Exempt, expedited or full board at Walden: which review path your study is on
You do not choose your review path at Walden, and you do not apply for one — the IRB office reads your Form A answers and routes the file itself. The categories underneath that routing are federal: exemption for narrowly defined low-risk designs, expedited handling for minimal-risk studies a designated reviewer can clear, and the convened board for everything that needs a vote. What you control is not the path. It is how legible your file makes the choice.
In a line — risk and data decide it: existing-data and minimal-risk designs travel Walden's streamlined path, while identifiable data, vulnerable populations and sensitive topics pull a file toward the convened board — where a majority vote approves, approves with stipulations, or disapproves. The routing is the university's call.
What are the three paths, before Walden touches them?
The architecture comes from the Federal Policy for the Protection of Human Subjects, which Walden's handbook adopts wholesale. Exemption, under 45 CFR 46.104, covers listed categories — among them surveys, interviews and observation of public behavior where identities cannot readily be ascertained or disclosure poses no real liability, research in established educational settings, and certain secondary uses of existing information. Expedited review, under 45 CFR 46.110, lets the IRB chairperson or experienced reviewers the chair designates clear minimal-risk studies that fit a published federal list — a list whose social-science entries read like a Walden capstone catalog: existing records collected for non-research purposes, voice and video recordings made for research, and studies of individual or group characteristics using surveys, interviews, focus groups and program evaluation. One asymmetry is worth memorizing: an expedited reviewer may approve, but may not disapprove — a study can only be turned down by the full, convened procedure. Full-board review is that procedure: the members meet, a quorum is present, and the file is decided by vote.
How does Walden actually route a study?
Quietly, and early. Walden's published process never asks the applicant to name a category; instead, Form A — the Description of Data Sources and Partner Sites — collects exactly the facts the routing depends on, and the Research Ethics Support Specialist's reply is already shaped by them. The process page says the one thing an applicant needs to know: the ethics approval process is streamlined for studies involving existing data or minimal risks. For the convened end of the spectrum, the handbook supplies the mechanics — a quorum at Walden is three-fifths of the members, and a majority vote can approve a study, approve it with stipulations, or disapprove it. Between those poles, the practical meaning of your path is how many readers your file must convince, and how formally.
| Posture | Who decides | Typical Walden shapes | What it asks of the file |
|---|---|---|---|
| Exempt-style handling | The IRB office, applying the federal categories | Anonymous staff surveys; analysis of de-identified records; public-records studies | Proof of anonymity or de-identification that actually holds, and a data use agreement where records are released |
| Streamlined / expedited | Chair or designated experienced reviewer | Minimal-risk interviews of professionals; program evaluation; recordings made for research | Clean consent, recruitment shown verbatim, instruments aligned with the approved proposal |
| Convened board | Quorum of members, majority vote | Vulnerable populations; sensitive topics; identifiable data with real stakes | Everything above, plus explicit risk mitigation the members can vote on without guessing |
Treat the middle column as orientation, not prophecy — the determination belongs to the university, and Walden's current handbook or IRB portal governs where any particular design lands.
What pulls a file toward the convened board?
Walden publishes its own early-warning list — the red-flag issues it asks researchers to raise in an IRB consultation while the proposal is still being drafted. The populations on it include minors, your own adult trainees, your own subordinates or patients, nursing home residents, prisoners, people with mental, emotional or physical impairments, people not fluent in English, undocumented immigrants, victims or witnesses of trauma, and active-duty military personnel with their federal gatekeepers. The topics include anything that could cost a participant a job or a promotion if disclosed, anything that might trigger an obligatory referral — addiction, severe depression, suicidality, violence — self-incriminating illegal activity, and the outcomes of new interventions. None of these makes a study unapprovable. Each of them adds a reader, a question and a required answer — which is why Walden's own advice is to bring them to the board's staff before the design hardens, not after the file is submitted.
Does the path change what you have to prepare?
Less than candidates hope, and in the opposite direction than they fear. The enclosure list is set by your data sources and sites — via Form A — not by the review category, so a streamlined file and a full-board file mostly contain the same documents; the board file simply has to survive more readers. Two genuine differences are worth knowing. First, designs built on existing records can sometimes proceed under a waiver of signed consent, since 45 CFR 46.116 lets an IRB waive consent requirements for minimal-risk research that could not practicably be conducted otherwise — Walden's clinical guidance points the same direction for de-identified chart reviews. Second, risk work moves forward in the file: for a convened board, the data security plan, the dual-role separation and the participant protections cannot be implicit anywhere, because members vote on what is written, not on what was intended.
Can you choose, argue or appeal the path?
You can inform it — precise Form A answers, a design that genuinely minimizes risk, anonymity that holds up — but you cannot select it, and at Walden you cannot appeal the outcome either: the handbook states that IRB decisions are not subject to appeal, while committing the board's chair to work with the researcher toward an approvable file. That pairing tells you how to spend your energy. Arguing with the routing wastes it; building the file so that the routing is easy — and so that whichever path it takes, every reader finds the risks already answered — is the whole game. A design that expects the convened board can also be worth reconsidering on its merits: Walden's guidance repeatedly steers minimal-risk alternatives — anonymous instruments, existing data — precisely because they protect participants and applicant alike, a trade examined further in the DNP quality-improvement question.
What to do next
If you are guessing which path your study is on — or a returned file has just told you the board sees more risk than you did — stop guessing. Hand the design to the desk through the contact page — the review is free — and we read it against the federal categories and Walden's published routing signals and give you the review-path call in writing, with the reasons. Then the desk builds and carries the entire file, whichever path it travels, until the approval email arrives — the study stays yours, the decision stays the board's. The documents any path will demand are inventoried in the Walden IRB application checklist, and the shorter answers live on the FAQ.
Sources
- Walden University, Research Ethics Review Process by IRB (streamlined for existing data and minimal risk; Walden sign-in may be required): academicguides.waldenu.edu/research-center/research-ethics/review-process
- Walden University Catalog & Handbook, Doctoral Learning and Resources (45 CFR 46 adoption; quorum; majority vote; no appeal): academics.waldenu.edu/handbook/learning-modalities/doctoral-research-resources
- Walden University, Red Flag Issues That Should Trigger a Research Ethics Consultation (Walden sign-in may be required): academicguides.waldenu.edu/research-center/research-ethics/red-flags
- 45 CFR 46.104, Exempt research: law.cornell.edu/cfr/text/45/46.104
- 45 CFR 46.110, Expedited review procedures: law.cornell.edu/cfr/text/45/46.110
- 45 CFR 46.116, General requirements for informed consent: law.cornell.edu/cfr/text/45/46.116
- OHRP, Categories of Research That May Be Reviewed Through an Expedited Review Procedure (1998): hhs.gov/ohrp/…/categories-of-research-expedited-review-procedure-1998
- Walden University, Research Ethics FAQs for Clinical and Intervention Settings (chart review and consent waivers; Walden sign-in may be required): academicguides.waldenu.edu/research-center/research-ethics/clinical-intervention